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1. Introduction 
Neuromyelitis optica (NMO) is an inflammatory disorder restricted to the spinal cord and 
optic nerves. Contrary to multiple sclerosis (MS), relapses of NMO are often strikingly severe 
and most NMO patients present stepwise neurological impairments. NMO treatments are 
aimed to prevent the relapses with the administration of various promising 
immunosuppressive drugs. However, relapse treatment is still a tricky problem. Since the 
largely used steroid treatment usually fails to control severe attacks, specific add-on treatments 
have to be considered in order to limit the stepwise increase of residual impairment. Given 
that a strong humoral response characterizes NMO physiology, one might assume plasma 
exchange (PLEX) to be particularly well adapted in severe NMO relapses.  
This chapter will analyze the relevant data of PLEX in the setting of NMO spectrum disorder. 
We will first outline the physiological grounds leading to the rationale of the PLEX treatment 
and the technical aspects of the procedure. Then we will assess the clinical results obtained in 
each type of attacks. Finally we will try to build an original concept linking the clinical results 
and the timing of PLEX onset with the dynamic of the inflammation inside the lesions.  
2. Physiopathology of NMO 
The physiopathology of demyelinating disorders is complex and may grossly be divided in 
two distinct parts: a cellular response implying lymphocytes, macrophages and 
granulocytes in NMO; and a humoral response involving many circulating components 
including antibodies, complement and cytokines which will be extravasated into the 
inflammatory sites where they will participate to the inflammatory cascade of events 
leading to the local lesion. We will briefly review the main physiopathological aspects of 
NMO and focus on the humoral response, which is especially suitable to be eliminated by 
PLEX upstream to the lesion. 
2.1 Physiopathology of NMO lesions 
2.1.1 Pathology 
A characteristic pathological pattern has been described in NMO (Lucchinetti et al., 2002). 
Lesions are infiltrated by neutrophils and eosinophils and wall capillaries are hyalinized. A 
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vasculocentric pattern of activated complement and immunoglobulin of IgG and IgM types 
is observed that mirrors the normal expression of AQP4. AQP4 expression is definitely 
reduced in normal appearing white matter and lost throughout the lesions. These 
modifications are the hallmark of NMO and could occur alone or associated with a wide 
range of lesions from mild demyelination to large necrosis. This pattern of lesion was 
classified in the pattern II of the Lassmann’s classification of the inflammatory lesions 
(Lucchinetti et al., 2000, 2002). 
Contrary to MS, T cells are rare in NMO lesions and probably had no major effect on the 
formation of the lesions (Saadoun et al., 2011). However T cells are probably involved 
upstream in physiopathological cascade in the earlier phases of the disease where a complex 
interplay leads to antigen sensitization and possibly in the initial opening of the blood-brain 
barrier (BBB) (Pohl et al., 2011).    
2.1.2 Specific antibodies and their epitopes 
The NMO-IgG antibody is an IgG1 directed against a surface epitope of the protein 
aquaporin-4 (AQP4) (Lennon et al., 2005). This antibody is detected with tissue-based 
immunofluorescence assays with a sensitivity and specificity for clinically defined NMO of 
more than respectively 60% and 90%. NMO-IgM theoretically coexits with NMO-IgG in 
about 10% of cases but significance is poorly known (Jarius et al., 2010a). Clinically 
diagnosed NMO patients share common clinical and evolutional characteristics according to 
the NMO-IgG status. Beyond the surrogate marker value of NMO-IgG, this marker is now 
used as a major diagnostic criterion (Wingerchuk et al., 2006) and delineates the NMO 
spectrum disorders that gather in a same entity both typical NMO and unusual or truncated 
clinical forms (Wingerchuk et al., 2007). 
Astrocytes closely interact with endothelial cells to maintain the CNS BBB. These cells 
express AQP4 in the apical domain of the membrane feet expansions situated close to the 
surrounded blood vessels. They are generally found as single tetramers, closely arranged in 
orthogonal arrays. This transmembrane protein is critically involved in the homeostasis of 
the water in the brain and interfaces with blood vessels, especially in the clearance of free 
water. Loss of perivascular AQP4 in the basal state results in cellular swelling, ostensibly 
due to a failure to eliminate water generated from cellular metabolism (Amiry-Moghaddam 
et al., 2003). Thus in NMO, since the interaction of NMO-IgG and AQP4 leads to a functional 
knock-out phenotype of AQP4, edema develops as a result of functional impairment of 
AQP4 although BBB is expected to be still intact, which may explain the paradoxical lack of 
gadolinium enhancement in most NMO lesions. Apart from water homeostasis, the removal 
of AQP4 from astrocytes membrane is associated with an impaired homeostasis of 
glutamate via the loss of function of EAAT2, a major glutamate transporter associated with 
AQP4 in a macromolecular complex (Hinson et al., 2008). The disruption of glutamate 
homeostasis initiates an excitotoxic mechanism damaging oligodendrocytes and ultimately 
leading to demyelination (Marignier et al., 2010). 
Virtually all the CNS astrocytes express AQP4, however some regions are enriched in AQP4. 
Those regions are the spinal cord gray matter, the posterior optic nerve, the floor of the 
fourth ventricle and the circum ventricular organs especially the area postrema, explaining 
the restriction of the sites of lesion characterizing NMO (Pittock et al., 2006a). Interestingly 
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circumventricular organs are also the only sites of the CNS expressing fenestrated capillaries 
favoring local passive diffusion of circulating antibodies.  
2.1.3 NMO-IgG and complement as key factors 
Clinical activity may correlate with the underlying NMO-IgG titres. NMO-IgG detection is a 
strong predictor of recurrence after an initial spinal or optic attack (Jarius et al., 2008, 2010b; 
Weinshenker, et al 2006). In few patients, NMO-IgG was high during flares and became 
negative during the stabilized disease following treatment, and in contrary, an initially 
seronegative patient became positive during a further attack (Weinstock-Guttman et al., 
2008). In the seminal work of Takahashi et al. (2007), NMO-IgG levels were positively 
correlated with both clinical severity (i.e. blindness) and radiological severity. Moreover a 
strong positive correlation was obtained between the NMO-IgG titres at the nadir of 
exacerbations and the spinal cord lesion length on MRI (Takahashi et al., 2007). In contrast, 
low NMO-IgG titres were observed during remission induced by immunosuppressive 
maintenance therapy (Jarius et al., 2008).  
In vitro, the binding of NMO-IgG to the extracellular domain of AQP4 reversibly down-
regulates its plasma expression. In the presence of active complement, this binding leads to 
strong complement activation and rapid cell destruction. NMO serum IgM is not AQP4-
specific and abundant IgM deposits in the NMO lesions may have passively diffused after 
the BBB disruption by the seminal focal complement activation initiated by NMO-IgG 
(Hinson et al., 2007).  
In an animal model of EAE with passive transfer of NMO-IgG, the transfer exacerbated EAE 
signs and the typical pathological characteristics were reproduced in treated rats (Kinoshita 
et al., 2009; Bradl et al., 2009). Direct injection of NMO-IgG in rat brains could reproduce the 
pathology but only when complement is coinjected (Saadoun et al., 2010)  
The NMO-IgG ability to lesion AQP4-transfected cells in the presence of complement was 
assessed with serum drawn from patients with mild and severe attacks. The percentage of 
cells lesioned by complement was strongly higher in presence of sera from patients with 
severe attacks, although lesion induced by sera from patients with mild attacks did not 
differ from negative controls or MS patients (Hinson et al., 2009). Thus the severity of the 
disease may be partly determined by intrinsic NMO-IgG characteristics to activate the 
complement. 
2.2 Proof of concept of PLEX in NMO 
As we already described, NMO lesions are associated with a strong IgG, IgM and 
complement deposition, typical of the pattern II in Lassmann’s classification. The NMO-IgG 
is involved in a complement-dependant toxicity against the astrocytes. All of these 
components -IgG, IgM, and complement- are targeted by plasma exchanges. By means of 5 
exchanges, all the exchanged molecules will drop to less than 20% of their initial level. By 
this way, antibodies and complement, which are the core of the pattern II lesions, are 
excluded from the circulating pool and cannot migrate anymore to the lesions.  
Although PLEX has long been used in various demyelinating disorders (Keegan et al., 2002), 
there is some clue that the pattern is a key determinant of PLEX efficiency. In a retrospective 
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study, Keegan et al. (2005) reported that all the patients suffering from demyelinating 
disorders and improved by PLEX had a biopsy proven pattern II lesion. None of the patients 
with any other kind of lesion improved. However all these patients were MS without NMO-
IgG and none were NMO (Keegan et al., 2005; Kale et al., 2009).  
All the aforementioned findings stress that circulating NMO-IgG and complements are the 
two main actors of the NMO pathogeny and why clearing them from blood with PLEX 
should be appropriate for special benefits. 
3. Plasma exchange procédure 
3.1 Principles and goals 
Basically, the goal of PLEX (or plasmapheresis) is to remove a given volume of patient’s 
plasma containing harmful targeted substances and to reinfuse an artificial plasma 
substitute in its place -the plasma exchange (Brecher, 2002).  
3.2 Technique 
PLEX are carried on in a nephrology or a resuscitation ward. Two high flow rate accesses 
are mandatory: an input line from patient to device (‘artery’) and a return line from device 
to patient (‘vein’). In continuous filtration, two needles are placed in both arms or groins in 
order to drawn out the blood of the body through an extracorporeal line connected to one 
needle, then blood is processed and reinfused continuously through the other needle. In 
case of discontinuous filtration, the separation and remixing are done in small batches 
through a single venous access in the groin where in and out cycles may alternate. 
Anticoagulation (citrate or heparin) is added to the blood pre-plasma filter to prevent from 
clotting. The removed blood is processed (apheresis procedure) in a cell separator that 
continuously separates plasma from cellular components (consisting of red and white blood 
cells and platelets) either by a centrifugation ring with permanent in and out flow, or by 
filtration through a porous membrane. Small molecules like cytokines as well as large 
molecules, such as albumin and immunoglobulin, are easily extruded from the blood 
compartment with a reported sieving coefficient >0.95 at a blood flow rate of 100 mL/min. 
The cleared cellular components are then combined with the replacement fluid (donor 
plasma or artificial albumin mixed with a saline solution) and returned to the patient 
through the needle in the other arm. A PLEX session is usually performed in 2 to 6 hours, 
depending on patient’s height, weight, viscosity of the blood and technical parameters. 
3.3 Kinetics of the target exchanged components. 
All the targeted components are distributed in the interstitium (extra-vascular 
compartment) by variable part. Large molecular weight compounds equilibrate slowly 
between the vascular space and the interstitium. Calculations of the rate of removal are 
simplified to first order kinetics. The relation curve of the achieved concentration of a 
plasma component C after a unique exchange of a given plasma volume V is an 
exponential inverse: C =C0.e-Y. The whole plasma volume can be approximated in an 
adult with the following formula:   
Estimated plasma volume (liters)= 0.07 x weight (kg) x (1-hematocrit).  
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The larger volume of plasma exchanged during each session clears a larger amount 
targeted circulating component. An exchange of one body plasma volume leads to the 
immediate clearance of 50% of the circulating component. A 1.3 body mass volume 
exchange that removes about 72% of C is generally agreed. Beyond, the volume to process 
increases massively for too little gain. However, according to the distribution of C in the 
interstitium, the achievement of the clearance of C will necessitate the use of multiple 
PLEX sessions separated by the time necessary for the equilibration of C concentration 
between interstitium and vascular spaces. The number and frequency of sessions should 
be evaluated according to the biological characteristics of the components to remove 
(synthesis level, vascular distribution, diffusion ability). An empirically driven number of 
4 to 6 sessions is usually scheduled. The durability of the immunomodulatory effect after 
PLEX is difficult to assess and will depend on the turnover rate of the targeted humoral 
components. Concomitant intensive immunosuppressive therapy (i.e. steroids, 
mitoxantrone, mycophenolate mofetil, rituximab) will be required to sustain the obtained 
depletive effect. 
3.4 Risks and side effects 
PLEX are contraindicated in case of ongoing infectious disease, precarious hemodynamics 
and active hemorrhage (heparin). Immediate side effects are related to the extracorporeal 
line: hemodynamic instability, vaso-vagal syndrome, numbness or tingling, venous 
puncture hazards with excessive local bleeding, septicemia or allergy. Since blood 
coagulation factors are all depleted by PLEX, hemostasis is affected in variable ways: first, a 
hypocoagulation state is immediately achieved by the global depletion of all the coagulation 
factors for half a day; at day 2, short life pro-coagulant factors are regained but 
antithrombin-III synthesis is delayed leading to a hypercoagulable state until day 3. 
Preventive anticoagulation with heparin is always required since the high risk of 
thrombosis. Persistently low fibrinogen levels have been described with the concomitant use 
of high dosage steroid infusion. In summary PLEX are generally well tolerated and now 
commonly and safely used. 
4. PLEX in severe attacks 
Various regimens of high doses of intravenous methylprednisolone are used in first line of 
treatment ranging from 3 g infused in 3 days, to 10 g in 5 to 10 days, depending on authors. 
There is no evidence in favor of one regimen or another and efficacy assessment has never 
been addressed. Moreover, even if steroids reduce the inflammatory cellular response by 
triggering apoptosis of lymphocytes, they are clearly not sufficient because poor outcomes 
are still a common issue even when steroid treatment is given immediately after onset. We 
wish to develop here the evidence for the effectiveness of PLEX that we have been largely 
using as an add-on therapy for more than 10 years.  
Of note, steroids were always used to treat relapse. When used the same day as PLEX 
procedure, steroids were infused at the end of each PLEX session. However 
methylprednisolone pharmacokinetics is characterized by a short half-life and PLEX 
demonstrated to have no effect on steroids biodisponibility (Assogba et al., 1988; Stigelman 
et al, 1984).  
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4.1 Spinal attacks 
PLEX proved to be efficient in central demyelinating diseases in a randomized sham-
controlled study (Weinshenker et al., 1999, 2001). Keegan et al. (2002) reviewed the clinical 
data from 59 patients who received PLEX for inflammatory demyelinating diseases, 
including 10 NMO and 6 acute transverse myelitis (ATM) cases. A moderate or marked 
improvement was obtained in half of NMO and ATM patient groups. The late final outcome 
at one year was more or less obtained during the first month after treatment in both groups, 
without regard to success or failure of treatment (Keegan et al., 2002; Brunot et al., 2011). A 
small number of case reports and few small studies were reported with variable issues. 
Judging improvement is even more complex due to the subjective classification of 
improvement in mild/moderate/marked instead of a quantified clinical exam (Brunot et al., 
2011; Keegan et al., 2002; Munemoto et al., 2011; Llufriu et al., 2009). Moreover the natural 
history of single spinal relapse in NMO has never been addressed, so any improvement bias 
after PLEX is inappreciable in the absence of a control group. Finally, most authors used 
PLEX as a rescue treatment given late after the onset. For example PLEX was delayed from 
onset by a mean of 3330 days in Brunot et al. (2011) and a median of 30 days 6 to 90 days 
in Llufiru et al. (2009). 
Although a synergistic effect of steroids and PLEX was long expected due to their 
complementary action, none of these studies compared PLEX-treated attacks with 
conventional steroid treatment given alone with add-on PLEX-treated attacks.  
We previously refined these results in a study of outcome after severe spinal attacks 
associated with NMO spectrum disorders (Bonnan et al., 2009a). We included 96 spinal 
attacks from 43 patients, divided in two groups: 1) a steroid-only group designed from 
historical patients treated with steroids alone; 2) an active group treated both with PLEX 
and steroids. Steroid infusion was started immediately after patient admission. PLEX 
decision was raised at the same time and started as soon as possible during the two days 
later. As a major difference with other groups, PLEX was never initiated as a delayed rescue 
treatment after a standard steroid treatment failure. Since PLEX therapy is mainly expected 
to minimize residual impairment, we used the ΔEDSS (calculated as the difference between 
residual and basal EDSS) as the main outcome. 
If we except 5 PLEX delayed due to difficult medevac reasons, PLEX were initiated by a 
mean of 5.4 ± 3.1 days after attack onset with a median of 4 sessions. 
There was no significant difference between the PLEX-treated and steroid-only groups for 
basal and acute EDSS (3.9 ± 2.9 vs 4.2 ± 2.9, and 7.9 ± 1.0 vs 8.0 ± 1.4; p=NS), however 
residual EDSS (5.1 ± 2.4 vs 6.8 ± 1.9, p<0.01) and mean ΔEDSS (1.2 ± 1.6 vs 2.6 ± 2.4, p<0.01) 
were significantly lower in the PLEX-treated group than in the steroid-only group.  
Basal EDSS dramatically influenced therapy outcome as shown in Table 1. During the first 
attack, although acute EDSS were similar in both groups (7.6 ± 1.2 vs 7.1 ± 1.5, p=NS), 
ΔEDSS and residual EDSS were dramatically reduced in the PLEX-treated group (2.1 ± 1.9 
vs 5.8 ± 2.0, p<0.01) given that acute EDSS was similar in this sub-group. In the two other 
sub-groups of basal impairment (EDSS 1.0 to 5.5 and EDSS ≥6.0), residual EDSS and ΔEDSS 
tended to be lower in PLEX-treated attacks but no statistical signification could be obtained 
due to the small size of these groups.  
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Basal EDSS 
null 
Basal EDSS 
1.0 to 5.5 
Basal EDSS 
≥ 6.0 
EDSS 
St 
(n=17) 
St+PLEX (n=7) p 
St 
(n=26) 
St+PLEX 
(n=13) 
p 
St 
(n=24) 
St+PLEX 
(n=9) 
p 
Basal 0 0 0.99 3.9±0.8 3.9±1.6 0.59 7.4±1.0 7.1±0.8 0.52 
Acute 7.1±1.5 7.6±1.2 0.52 7.6±1.3 7.6±1.1 0.67 8.9±0.9 8.6±0.6 0.24 
Residual 5.9±1.9) 2.1±1.9 <.01 5.8±1.6 5.1±1.1 0.21 8.5±1.1 7.6±1.0 0.05 
ΔEDSS 5.9±1.9 2.1±1.9 <.01 2.0±1.5 1.2±1.6 0.10 1.1±0.8 0.5±0.8 0.11 
Table 1. Disability measured as EDSS during spinal attacks stratified with basal impairment. 
St: steroid-only treated group; St+PLEX: steroid and PLEX-treated group. Values are given 
as mean±SD (from Bonnan et al., 2009a). 
The classical Lazarus effect, defined as a very short-term dramatic improvement 
(Weinshenker et al., 2000), was rather unusual in our group but our study was not designed 
to analyse short-term improvement. The patients who experienced this effect have all 
received a very early treatment (less than 2 days). In Magana et al. (2011), patients who 
exhibited functional improvement did so within a median of 4 days (third PLEX), although 
a minority (6%) exhibited a delayed response (more than 2 months). 
Minor side effects occurred in 24% of PLEX treated attacks and resulted in PLEX 
interruption once (84-year-old patient with pulmonary embolism).  
In summary, PLEX-treated patients achieved a significantly better outcome after a spinal 
attack, especially if PLEX was given during the first attack. The exact effect of PLEX in 
previously impaired patients should be validated in a larger multicentric cohort. As PLEX 
proved to be a promising treatment in spinal attacks, it would now be unethical to design a 
study with a sham-treated control group.  
Predictors of good outcome were studied in a large group of PLEX including 26 NMO 
patients (Bonnan et al., 2009a). The only good outcome predictor was normal or brisk 
reflexes in acute phase (Magana et al., 2011). Surprisingly a short PLEX delay was associated 
with a good outcome in a first study (Keegan et al., 2002) but had no effect in a second 
study, although one should remind that median PLEX delay (23 days) was delayed in this 
later compared to our group. The same PLEX response rate was obtained irrespective of 
NMO-IgG serostatus in our cohort and in the Mayo Clinic cohort (Magana et al., 2011). 
As a practical consequence, faced with a patient suffering from a severe relapse, the 
knowledge of NMO-IgG status should not be required to start PLEX as soon as possible, 
since PLEX was found efficient in NMO-IgG negative patients. 
4.2 Optic attacks 
Visual impairment in NMO is very severe. We previously showed that an immediate 
unilateral blindness occurred in a third of patients after the first optic neuritis (ON), and 
generally two attacks are sufficient to cause a definitive loss of vision (Merle et al., 2007). 
Few PLEX were undertaken after ON and a quick dramatic recovery is usual as we also 
observed (Bonnan et al., 2009b; unpublished results). Depending authors, PLEX were used 
immediately (Bonnan et al., 2009b) or as a delayed add-on therapy (Schilling et al., 2006; 
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Watanabe et al., 2007a; Trebst et al., 2009; Yoshida et al., 2010). After pooling severe ON 
patients (acute visual acuity<1/10°) from available studies (Schilling et al., 2006; Ruprecht et 
al., 2004; Trebst et al., 2009) with ours (Bonnan et al., 2009b and unpublished results), data 
were gathered for 39 eyes. PLEX were given in median of 19 days in patients who recovered 
a visual acuity more than 1/10° (considered here as a treatment success) but 41 days in 
treatment failure. A clear effect of PLEX delay was observed since success rate was 8/8 
(100%) during the first 11 days, than 4/7 (57%) from days 12 to 22, and 7/13 (53%) from 
days 23 to 73. Moreover, even when patients recovered, averaged residual VA tended to be 
lower in delayed PLEX patients (Figure 1).  
Interestingly, the spontaneous recovery (>1/10°) after severe ON treated by steroids alone 
was about 40% in our cohort (from Merle et al., 2007), which is very close to the recovery 
obtained in the two last groups of late PLEX. In conclusion, strong clues support that PLEX 
change the outcome of severe ON only when they are given early, however broader studies 
are still lacking to confirm this hypothesis. 
 
 
Fig. 1. Metanalysis of residual Visual Acuity as a function of PLEX delay (days) in severe 
ON attacks (acute VA<1/10°). See text. 
4.3 Brain attacks 
Apart from optico-spinal attacks, severe brain attacks are described in NMO, especially 
involving hypothalamus and medulla. Those lesions are usually severe and associated with 
blindness, central endocrine disorders or quadriplegia with respiratory failure. Brain lesions 
are common but are mostly asymptomatic (Pittock et al., 2006b). However symptomatic 
lesions involving supratentorial white matter are exceptional and extensive (Pittock et al., 
2006b). Even if a favourable outcome after PLEX has been reported in a few severe cases 
(Viegas et al., 2009; Watanabe et al., 2009ab), comparative data are still lacking.  
Posterior reversible encephalopathy syndrome (PRES) is an encephalopathy with 
consciousness and visual disturbances with rapidly reversible changes on MRI consistent 
with vasogenic edema. PRES are triggered by blood pressure instability or fluid stresses 
VA 
Days 
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due to various causes. It seems to occur more often than coincidental in NMO patients: 5 
out of 70 consecutive NMO-IgG patients evaluated at Mayo Clinic (Magana et al., 2009); 2 
out of 5 in Hadassah Medical School, Israel (Eichel et al., 2008). Authors proposed that the 
auto-immune mediated disruption of the AQP4 water channel function may predisposes 
to PRES at comparable levels of acute illness (Magana et al., 2009). PLEX was involved as 
a trigger in one case with a good final outcome. In few cases, PLEX were implemented as 
curative treatment with an overall good outcome (Eichel et al., 2008; Magana et al.,  
2009).  
5. Timing of PLEX: evolving to a key concept 
Besides knowing PLEX are effective and safe, the central question remains: is PLEX 
necessary as-soon-as and as-often-as possible? Prospective, randomised, multi-centre 
clinical trials would be required to definitively answer the question. For most authors, to 
date PLEX are considered as an add-on rescue treatment after steroid failure. The European 
recommendation from EFNS is to start with an early steroid course no matter the severity 
(Sellner et al., 2010). Early escalation with PLEX is only recommended after a failure of a 
second course of steroids, that is to say that PLEX initiation may be postponed for more than 
a week. As we demonstrated before, PLEX efficiency is depends on the timing of initiation, 
ranging from immediate dramatic improvement (the Lazarus effect) to no effect according to 
whether they are given early or very late. We propose to regress to the dynamic of the 
inflammatory NMO lesions to explain why PLEX efficiency is strongly dependant of the 
timing of their onset.  
5.1 Evidence for reversible dysfunction preceding irreversible tissue loss. 
As we described above, the lesion is the consequence of a cascade of reversible events, 
susceptible to an external action.  One could abruptly divide this cascade in two main 
points: a direct toxic action upon astrocytes and a bystander effect on oligodendrocytes and 
axons. Astrocyte dysfunction is initiated by the binding of NMO-IgG to the extracellular 
domain of AQP4 on the foot of the astrocyte membrane. In vitro, this binding reversibly 
down-regulates AQP4 plasma expression. The presence of fresh complement leads to a 
strong complement activation and a rapid cell destruction. IgG titres strongly correlates 
with the cytotoxic effect (Kalluri et al., 2010). By the other way, the removal of AQP4 from 
astrocytes membrane, due to internalization or cell death, impairs the clearance of free 
glutamate due to the dysfunction of the transporter EAAT2. The glutamate progressively 
accumulates and initiates an excito-toxic mechanism upon oligodendrocytes, ultimately 
leading to demyelination (Marignier et al., 2010).  
The time sequence of these events was studied in lesions induced by direct mouse brain 
injection with NMO-IgG and complement (Saadoun et al., 2010). Loss of AQP4 and GFAP, 
and myelin breakdown were evident 7h following the injection. The inflammatory cells 
infiltration became evident later. Within 12h, axonal injury became prominent. By day 7, 
axonal loss and dying neurons were evident. Finally, one could suppose that a very early 
intervention targeting astrocytes dysfunction may prevent the progression to the bystander 
effect.  
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5.2 Evidence supporting an early treatment  
The influence of treatment delay upon outcome has been addressed in a single study of first 
ON receiving steroid treatments (Nakamura et al., 2010). The outcomes were both visual 
acuity and the width of the retinal fibers layer evaluated with optic tomography (OCT). 
Patients were divided into two groups: one group with a good visual outcome, including a 
high residual visual acuity and high RFL; and a second group with a poor visual outcome in 
terms of low acuity and low RFL. Very interestingly, the two groups were similar in all the 
parameters except one: patients with a good outcome received steroids with a lower mean 
delay after ON onset, by a mean of 1.8±1.1 days compared to 7.8±3.8 in patients with a poor 
outcome. This study is the first proof that a delayed infusion of steroids is associated with a 
poorer outcome. A similar effect of treatment delay, although unknown, should be expected 
in spinal attacks. Even if no proof is yet available after a PLEX treatment, these clues could 
be gathered that early PLEX would improve the prognosis (see above).  
In spinal attacks treated with PLEX, early initiation of treatment was one out of the 
predictors of good outcome (Keegan et al., 2002). In a larger study encompassing attacks 
from various demyelinating disorders, success rates were stratified by delay: improvement 
occurred in 83% when given before day 15, but fell to 43 after 2 months (Llufriu et al., 2009). 
Moreover the dramatically very short-term improvement, called Lazarus effect 
(Weinshenker et al., 2000), is sometimes observed after severe attacks receiving a very early 
treatment with PLEX and steroids. However, this earliness responsibility on the Lazarus 
effect remains elusive since no study is available on this rather unusual effect.  
5.3 Lesion stages and PLEX action: ‘time is cord and eyes’ 
In the light of the available data, we postulate a link between the staging of NMO lesion and 
the PLEX effect upon clinical and radiological outcome (Figure 2).  
Stage 1 (first hours): acute attack provokes for hours an astrocyte dysfunction (by NMO-
IgG binding on AQP4 leading to internalization) mainly expressed by an edema. This purely 
edematous lesion could be immediately reversible by the clearance of NMO-IgG preventing 
the loss of astrocytes and the excitotoxic cascade. Clinical and radiological recovery after 
PLEX is dramatic and explains the Lazarus effect. Stage 2 (days): the loss of EAAT2 induces 
an excitotoxic effect of glutamate on oligodendrocytes leading progressively to 
demyelination and axonal loss. Astrocytes loss initiates a self-sustained excitotoxic process 
henceforth independent from NMO-IgG persistence. Even if the extraction of NMO-IgG and 
complement by PLEX ends the astrocytes aggression. A variable amount of them has been 
already lost and excitotoxic effects upon oligodendrocytes are evident. Variable amount of 
tissue is lost as visible on MRI and recovery is incomplete. Stage 3 (weeks): atrocytes, 
oligodendrocytes and axonal loss is prominent, engulfed in large areas of necrosis. PLEX is 
almost useless. Neural tissue remains cavitated or atrophic on MRI and no recovery will be 
expected. 
We propose to reconsider PLEX as a major part of the treatment of severe NMO attacks and 
suggest that PLEX could be given systematically in severe relapses of NMO, extended 
transverse myelitis or bilateral severe ON resistant to steroids. Moreover, when given they 
should be started as soon as possible with steroids.  
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Fig. 2. Putative PLEX effect depending of the three main stages of the lesion.  
6. PLEX as preventive treatment  
Since NMO-IgG positivity is both predictive of attacks and severity, achieving a low 
concentration of plasmatic antibodies remains a goal to achieve. Besides 
immunosuppressive drugs, PLEX have been used to achieve a sustained depletion of NMO-
IgG and complement. Favourable cases have been reported but studies are lacking 
(Miyamoto et al., 2009). Miyamoto et al. (2009) proposed to use PLEX as preventive 
treatment as an add-on therapy after immunosuppressive drugs failure. 
7. Preventive treatments and future avenues 
The natural history of NMO leads all the patients to a deep impairment in a stepwise 
fashion without progressive phase. In our study, 5 years after the onset, 70% of patients 
suffered from a unilateral loss of vision and almost half of them from a bilateral loss of 
vision (Merle et al., 2007). After 8 years, half of the patients had suffered from a severe 
myelitis and become chair-bound (Cabrera-Gomez et al., 2009). The mortality rate was very 
high before immunosuppressive drugs but dropped since they are largely used (Cabre et al., 
2009). The exact role of recurring PLEX along the remaining attacks to tune the outcome to a 
low impairment has not yet been addressed but remains most probable considering this 
striking epidemiological change of mortality in French West Indies. 
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7.1 Immunosuppressive maintenance 
Contrary to MS, cumulative evidence accumulates that interferon beta had no effect on 
activity rate and worsens some patients, especially in lupus-associated NMO (Uzawa et al., 
2010). When IFN is compared to immunosuppressive drugs, a dramatic reduction of 
annualized relapse rate (ARR) is obtained (Papeix et al., 2007). Rituximab and 
mycophenolate mofetil were well tolerated and dramatically reduced ARR (Jacob et al., 
2008; Jacob et al., 2009). A favorable action of mitoxantrone was reported in few cases 
(Weinstock-Guttman et al., 2006). In a group of 32 patients treated with mitoxantrone in our 
centre, a dramatic drop in ARR was obtained from a mean rate of 1.8 to 0.3 and sustained 
over 5 years (Cabre, personal communication). The choice in one these three drugs should 
mostly be driven by safety concerns since no comparative study or recommendation is 
readily available. Low dose steroids were reported to be effective in a few patients, however 
these data needs further studies with more patients. Various others treatments 
(cyclophosphamide, azathioprine, venous immuno-globulins) have been used in isolated 
cases where no general conclusion could be drawn upon ARR action. However 
cyclophosphamide is commonly used to treat lupus in overlapping cases of NMO (Polgar et 
al., 2011). 
7.2 New strategies for the future 
Since the lesion severity mostly depends on the initial and definitive depth of the loss of 
AQP4 and astrocytes, future treatments strategies may be directed upon AQP4 preservation. 
Small molecules or monoclonal antibodies could be used to prevent NMO-IgG binding to 
AQP4 and to block the physiopathological cascade upstream (Verkman et al., 2011; Yu et al., 
2011). Another strategy may deplete pathogenic antibodies by apheresis using dedicated 
immunoadsorption systems as previously described in myasthenia gravis (Zisimopoulou et 
al., 2008) and in various extra neurological disorders. However the value of this technique is 
less clear in disorders like MS (De Andres et al., 2000; Moldenhauer et al., 2005) where 
pathology is broader than a specific antibody. No experience is yet available in the NMO 
setting. Lymphocytapheresis was successfully described in isolated cases of resistant attacks 
(Aguilera et al., 1984, Nozaki et al., 2006). A complementary approach may target the 
complement system with newly developed anti-complement recombinant antibodies at 
various levels, with preliminary promising results (Saadoun et al., 2010). Such future 
treatments may be aimed at preventing or curing the attacks. During attacks, 
neuroprotective treatments could be used to prevent the oligodendrocytes loss induced by 
the excitotoxic action of glutamate. 
Animal models gave clues to dynamic mechanisms evolving over time and appear suitable 
to address the effect of those various early therapeutic interventions directed to halt or 
prevent ongoing lesions (Saadoun et al., 2010). 
8. Conclusion 
PLEX, in synergy with steroids, could be a major treatment of relapses, aimed at preventing 
cumulative disability. PLEX is a safe and efficient add-on therapy in NMO. Since PLEX 
proved to be effective regardless of NMO-IgG status, NMO-IgG status should not be 
required to initiate PLEX. These preliminary results suggest that PLEX may modify the 
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short prognostic of NMO relapses. Immunosuppressive drugs are necessary to prevent 
further relapses but no recommendation is yet available.  
Animal models have confirmed that mechanisms leading to lesion evolve over hours and 
days. Those models should be able to confirm that early therapeutic intervention directed to 
halt the ongoing lesions should be even more dramatic in an early narrow therapeutic 
window. 
The next steps should be to concentrate upon large multicentric therapeutic trials in order to 
validate the therapeutic procedure. However we are aware that good trials against placebo 
could be difficult to accept since this is an extremely devastating disease. The take-away 
messages are: undertaking PLEX in severe relapses and the importance of starting treatment 
as soon as possible. 
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